ClinicalTrials.gg
RecruitingNCT06078969Updated Feb 1, 2024

Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

A Phase 2 interventional study of Prednisone in Langerhans Cell Histiocytosis of Bone, sponsored by Shanghai Changzheng Hospital. Recruiting at 1 site in China. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Shanghai Changzheng Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.

Planned enrollment
3rd of 17
118 · median 40
Started
2023
with 1 other
Phase 2
10 of 17
5 open now
Primary completion
2027-09
later than 7 of 12 live
Registered
9th of 17
by date
Lead sponsor
1 of 17
Shanghai Changzheng Hospital

Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 7 of the 12 other live ones, and was the 9th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Histiocytosis, Langerhans-Cell with a site in China, or all of them as a file.
02

Study summary

Langerhans cell histiocytosis (LCH) of bone is a benign-tumor-like osteolytic lesion in childhood and adolescence, which is characterized by the aberrant activation of antigen presenting cells. Rather than the multi-system involvements of LCH, no standard or widely-accepted therapeutic regimens were established for LCH of bone. In the previous clinical practice, several LCH patients obtained remarkable pain relief after taking prednisone. Therefore, the investigators aim to conducting a multi-center, open-labelled, randomized-controlled, Phase II study to investigate the efficacy and safety of oral prednisone in treating LCH of bone in children and adolescents. The enrolled patients will be randomly recruited to the following groups: (1) Oral prednisone [Test group); (2) Regular observation [Control group].

03

Conditions studied

  • Langerhans Cell Histiocytosis of Bone

Keywords

  • Langerhans cell histiocytosis
  • Bone
  • Single-system
  • Children
  • Adolescents
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathological diagnosis of Langerhans cell histiocytosis (LCH) of bone;
  • Single-system involvement (skeletal system);
  • No need of surgical intervention;
  • Must be able to swallow tablets;
  • Signing form.

Exclusion criteria

Exclusion Criteria:

  • Multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system);
  • Need of surgical intervention (e.g. pathological fracture and/or spinal cord compression)
  • allergy;
  • Immunodeficiency;
  • Severe infection;
  • Insulin dependent/independent Diabetes;
  • Having taken glucocorticoid in the past two weeks;
  • Not capable of swallowing tablets;
  • Without signed inform.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Oral prednisone

    Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months

    Drug: Prednisone

  • No intervention
    Regular observation

    Regular observation and follow up without medication

Interventions

  • For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Any evidence proving the disease progression

    Time frame: 2 years

Secondary outcomes

  1. Local control rate

    radiological examinations of local lesion status

    Time frame: 2 years

  2. Pain relief

    The Visual Analogue Scale (Minimum: 0; Maximum: 10 scores), is used to evaluate the degree of pain relief. The higher scores mean a worse outcome.

    Time frame: 2 years

  3. Adverse effect rate

    side effects related to the prednisone

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Stull MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics. 1992 Jul;12(4):801-23. doi: 10.1148/radiographics.12.4.1636041. PubMed 1636041 ↗
  • Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. doi: 10.1182/blood-2012-09-455774. Epub 2013 Apr 15. PubMed 23589673 ↗
  • Mitchell P, Ezeokoli EU, Borici N, Schleh E, Montgomery N. Treatment and Outcomes of Unifocal and Multifocal Osseous Pelvic Langerhans Cell Histiocytosis Lesions in a Pediatric Population. Cureus. 2022 Aug 27;14(8):e28470. doi: 10.7759/cureus.28470. eCollection 2022 Aug. PubMed 36176854 ↗
  • Baptista AM, Camargo AF, de Camargo OP, Odone Filho V, Cassone AE. Does adjunctive chemotherapy reduce remission rates compared to cortisone alone in unifocal or multifocal histiocytosis of bone? Clin Orthop Relat Res. 2012 Mar;470(3):663-9. doi: 10.1007/s11999-011-2162-x. PubMed 22052526 ↗
  • Zhong N, Xu W, Meng T, Yang X, Yan W, Xiao J. The surgical strategy for eosinophilic granuloma of the pediatric cervical spine complicated with neurologic deficit and/or spinal instability. World J Surg Oncol. 2016 Dec 7;14(1):301. doi: 10.1186/s12957-016-1063-6. PubMed 27923375 ↗
  • Tang X, Gao J, Ma ZG, Guo X, Li Q, Wan Z, Sun JJ. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Ann Med. 2021 Dec;53(1):1537-1546. doi: 10.1080/07853890.2021.1966085. PubMed 34459688 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

Time frame: 1 year

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2027, 46 months after the start.

Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 85. This study's planned 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 12, 2023
StartActual
Nov 4, 2023
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06078969
Collaborators
First Affiliated Hospital of Zhejiang University, Peking University Third Hospital, National Sun Yat-sen University, Beijing Children's Hospital, Henan Cancer Hospital, Tianjin Hospital, First Affiliated Hospital, Sun Yat-Sen University, Second Hospital of Jilin University, Peking University People's Hospital, Jinling Hospital, China, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University
Responsible party
Jianru Xiao (Professor, Chief Surgeon, Shanghai Changzheng Hospital) — Principal investigator
First posted
Oct 12, 2023
Start date
Nov 4, 2023
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion